NICE approves rivaroxaban for DVT and recurrent VTE

The direct factor Xa inhibitor rivaroxaban has been recommended for NHS use in two new indications.

It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY
It is estimated that there will be over 46,000 cases of acute DVT in England and Wales during 2012 | SCIENCE PHOTO LIBRARY

NICE has recommended rivaroxaban (Xarelto) as an option for treating deep vein thrombosis (DVT) and for preventing recurrent DVT and pulmonary embolism after a diagnosis of acute DVT in adults.

The anticoagulant can also be prescribed on the NHS to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to prevent venous thromboembolism (VTE) following total hip or knee replacement. 

Further details

NICE guidance on rivaroxaban in DVT

Further information:

View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...